The Vancouver-based company has cultivation, extraction, formulation and distribution assets woldwide
ICC markets and sells CBD products derived from Swiss, German, Serbian and Croatian industrial hemp inventories
The company also builds and operates high-quality, low-cost cannabis production, processing and distribution facilities
It has extensive agreements to cultivate and distribute cannabis and CBD products
What ICC does:
ICC International Cannabis Corp (CSE:WRLD) (OTCMKTS:KNHBF) is on a clear path to be the first publicly listed, globally focused, pure cannabis play.
With a diversified portfolio of subsidiaries, the Vancouver-based company has cultivation, extraction, formulation and distribution assets in the UK, Denmark, Poland, Switzerland, Germany, Macedonia, Bulgaria, Greece, Italy, Portugal, Malta, Colombia, Argentina, Australia, South Africa and Lesotho.
Besides acquiring cultivation and distribution assets, ICC markets and sells CBD products derived from its Swiss, German, Serbian and Croatian industrial hemp inventories, and reaps the benefits of its 2019 cannabis production from key licenses in the European Union.
It plans to leverage its portfolio of brands as well as its distribution network of more than 39,000 European pharmacies to maximize margins and profitability.
The company also builds and operates high-quality, low-cost cannabis production, processing and distribution facilities worldwide.
ICC continues to grow with extensive agreements to cultivate and distribute cannabis and CBD products. A major goal is to inspire holistic wellness through the design, development and production of innovative and high-performing cannabis products and facilities.
How's it doing:
In April this year, ICC acquired nearly half of Wayland Group Corp’s (CSE:WAYL) (OTCMKTS:MRRCF) international assets and license portfolio.
Over three years, Wayland will supply ICC with 10,000 kg annually of dried cannabis flower grown at Wayland’s Langton, Ontario production facility. The cannabis will be distributed across medical cannabis markets in Europe and is expected to pay ICC more than 8 euros per gram.
ICC is also establishing itself as a brand leader, forging a licensing deal with Authentic Brands Group to market and distribute cannabidiol-derived health and wellness products throughout Europe under the Marilyn Monroe, Elvis Presley, Greg Norman, Tretorn, Aeropostale, and Frederick’s of Hollywood brands.
The company has steadily expanded its portfolio while continuing to evaluate potential cannabis and CBD-centric assets in a variety of high-growth jurisdictions, including Uruguay, Portugal, Malta, Costa Rica, Seychelles and Switzerland.
Significantly, in July, ICC revealed it planned to develop, alongside some big names in the drugs world, the world's first cannabinoid biosynthesis platform allowing it to mass produce cannabis compounds more cheaply than conventional methods.
Together with Biotti Technologies, in which it is invested, ICC has struck an advisory agreement with Pfizer, Bristol-Myers Squibb, and Biogen advisor and cannabinoid expert Dr. Alexandros Makriyannis. And that deal came hot on the heels of an exclusive supply and commercial rights agreement with medical cannabis company NUBU Pharmaceuticals in New Zealand, in which ICC will supply NUBU with a suite of full-spectrum pharmaceutical grade medical cannabis products.
ICC is highly focused on a large and undeveloped emerging market for CBD in Europe, estimated to be worth C$66.8 billion by 2020.
Because European governments were early adopters of CBD, the product is readily available as an over-the-counter product, stocked in local pharmacies and available online. ICC estimates product demand to outstrip supply by 5 to 1.
Auxly Cannabis Group Inc (TSV:XLY) has invested $5 million into ICC through convertible debentures, effectively expanding the reach of both companies to 22 countries across five continents.
- 35,000 kg three-year EU-GMP medical cannabis import agreement with Wayland group
- 2,400 kg of CBD isolate produced in 2018
- 50,000 kg of CBD isolate in 2019
- More than 2,700 cannabis strains
- 80,000 retail outlets, pharmacies and stores
- 19 licenses for cultivation on four continents
- 740,000 kg of forecasted dried cannabis production from outdoor cannabis cultivation
What the CEO says:
To steer global growth, longtime cannabis executive David Shpilt was named CEO in April, replacing Eugene Beukman, who shifted to a seat on the board.
Shpilt spoke bullishly about his future at ICC, saying: “Together with International Cannabis, I look forward to the continued enhancement of excellence in cannabis, lifestyle, health care and design.”